A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

This study tests whether adding an immunotherapy drug called camrelizumab to radiation therapy improves outcomes for women with early-stage triple-negative breast cancer (a type that does not respond to hormone therapies or HER2-targeted drugs) after mastectomy. **You may be eligible if...** - You are a woman aged 18–74 with confirmed triple-negative breast cancer - Your tumor is large or has spread to lymph nodes (specific staging criteria apply) - You are planning breast-conserving radiation therapy after mastectomy - Your organ function (blood counts, liver, kidneys) meets acceptable levels **You may NOT be eligible if...** - You have received prior treatment for this breast cancer - You have significant organ dysfunction - You are pregnant or breastfeeding - You have an active autoimmune condition Talk to your doctor to see if this trial is right for you.